Biotechs are always battling for funding but the fight has become particularly fierce for the small and medium-sized enterprises (SMEs) which are trying to tackle the huge challenge that is antimicrobial resistance (AMR) poses.
Peter Jackson, executive director at the UK's AMR R&D Centre, is well placed to comment the struggles these smaller companies...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
